List of Twirla drug patents
Twirla is owned by Agile.
Twirla contains Ethinyl Estradiol; Levonorgestrel.
Twirla has a total of 3 drug patents out of which 0 drug patents have expired.
Twirla was authorised for market use on 14 February, 2020.
Twirla is available in system;transdermal dosage forms.
The generics of Twirla are possible to be released after 26 August, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747888 | AGILE | Dermal delivery device with in situ seal |
Jul, 2028
(5 years from now) | |
| US9050348 | AGILE | Dermal delivery device |
Jul, 2028
(5 years from now) | |
| US8246978 | AGILE | Dermal delivery device with reduced loss of its volatile components |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 14, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: SYSTEM;TRANSDERMAL
TWIRLA family patents
15
United States
2
Japan
2
European Union
1
Canada
1
Georgia
1
Brazil
1
China
1
New Zealand
1
Australia
1
EA
1
Spain
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic